Real-time MR Imaging with Gadoteridol Predicts Distribution of Transgenes After Convection-enhanced Delivery of AAV2 Vectors

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2010 Jun 17

PMID 20551915

Citations 44

Authors

Xiaomin Su

Adrian P Kells

Ernesto A Salegio

Ernesto Aguilar Salegio

R Mark Richardson

Piotr Hadaczek

Janine Beyer

John Bringas

Philip Pivirotto

John Forsayeth

Krystof S Bankiewicz

Affiliations

Soon will be listed here.

Abstract

Gene therapies that utilize convention-enhanced delivery (CED) will require close monitoring of vector infusion in real time and accurate prediction of drug distribution. The magnetic resonance imaging (MRI) contrast agent, Gadoteridol (Gd), was used to monitor CED infusion and to predict the expression pattern of glial cell line-derived neurotrophic factor (GDNF) protein after administration of adeno-associated virus type 2 (AAV2) vector encoding human pre-pro-GDNF complementary DNA. The nonhuman primate (NHP) thalamus was utilized for modeling infusion to allow delivery of volumes more relevant to planned human studies. AAV2 encoding human aromatic L-amino acid decarboxylase (AADC) was coinfused with AAV2-GDNF/Gd to confirm regions of AAV2 transduction versus extracellular GDNF diffusion. There was a close correlation between Gd distribution and GDNF or AADC expression, and the ratios of expression areas of GDNF or AADC versus Gd were both close to 1. Our data support the use of Gd and MRI to monitor AAV2 infusion via CED and to predict the distribution of GDNF protein after AAV2-GDNF administration.

Citing Articles

Neurosurgical gene therapy for central nervous system diseases.

Patel R, Nanda P, Richardson R Neurotherapeutics. 2024; 21(4):e00434.

PMID: 39191071 PMC: 11445594. DOI: 10.1016/j.neurot.2024.e00434.

The Influence of Size on the Intracranial Distribution of Biomedical Nanoparticles Administered by Convection-enhanced Delivery in Minipigs.

Amirrashedi M, Jensen A, Tang Q, Straathof N, Ravn K, Pedersen C ACS Nano. 2024; 18(27):17869-17881.

PMID: 38925630 PMC: 11238734. DOI: 10.1021/acsnano.4c04159.

PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma.

Mueller S, Kline C, Stoller S, Lundy S, Christopher L, Reddy A Neuro Oncol. 2023; 25(11):2074-2086.

PMID: 37318058 PMC: 10628948. DOI: 10.1093/neuonc/noad105.

Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson's disease.

Rocco M, Akhter A, Ehrlich D, Scott G, Lungu C, Munjal V Mol Ther. 2022; 30(12):3632-3638.

PMID: 35957524 PMC: 9734022. DOI: 10.1016/j.ymthe.2022.08.003.

Translational Approaches for Brain Delivery of Biologics via Cerebrospinal Fluid.

Sadekar S, Bowen M, Cai H, Jamalian S, Rafidi H, Shatz-Binder W Clin Pharmacol Ther. 2022; 111(4):826-834.

PMID: 35064573 PMC: 9305158. DOI: 10.1002/cpt.2531.

References

Wright J, Qu G, Tang C, Sommer J . Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Devel. 2003; 6(2):174-8. View

Lang A, Gill S, Patel N, Lozano A, Nutt J, Penn R . Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006; 59(3):459-66. DOI: 10.1002/ana.20737. View

Krauze M, McKnight T, Yamashita Y, Bringas J, Noble C, Saito R . Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res Brain Res Protoc. 2005; 16(1-3):20-6. DOI: 10.1016/j.brainresprot.2005.08.003. View

Varenika V, Dickinson P, Bringas J, LeCouteur R, Higgins R, Park J . Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg. 2008; 109(5):874-80. PMC: 2725182. DOI: 10.3171/JNS/2008/109/11/0874. View

Kells A, Hadaczek P, Yin D, Bringas J, Varenika V, Forsayeth J . Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci U S A. 2009; 106(7):2407-11. PMC: 2650169. DOI: 10.1073/pnas.0810682106. View

Hamilton J, Morrison P, Chen M, Harvey-White J, Pernaute R, Phillips H . Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin. Exp Neurol. 2001; 168(1):155-61. DOI: 10.1006/exnr.2000.7571. View

Salegio E, Kells A, Richardson R, Hadaczek P, Forsayeth J, Bringas J . Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders. Hum Gene Ther. 2010; 21(9):1093-103. PMC: 2936496. DOI: 10.1089/hum.2010.040. View

Yamashita Y, Krauze M, Kawaguchi T, Noble C, Drummond D, Park J . Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts. Neuro Oncol. 2006; 9(1):20-8. PMC: 1828110. DOI: 10.1215/15228517-2006-016. View

Krauze M, Saito R, Noble C, Tamas M, Bringas J, Park J . Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg. 2005; 103(5):923-9. PMC: 3816104. DOI: 10.3171/jns.2005.103.5.0923. View

10.

Yin D, Valles F, Fiandaca M, Bringas J, Gimenez F, Berger M . Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage. 2009; 54 Suppl 1:S196-203. PMC: 2895968. DOI: 10.1016/j.neuroimage.2009.08.069. View

11.

Fiandaca M, Forsayeth J, Dickinson P, Bankiewicz K . Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics. 2008; 5(1):123-7. PMC: 2719019. DOI: 10.1016/j.nurt.2007.10.064. View

12.

Raghavan R, Brady M, Rodriguez-Ponce M, Hartlep A, Pedain C, Sampson J . Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus. 2006; 20(4):E12. DOI: 10.3171/foc.2006.20.4.7. View

13.

Kroll R, Pagel M, Muldoon L, Neuwelt E . Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery. 1996; 38(4):746-52; discussion 752-4. View

14.

Weihe E, Depboylu C, Schutz B, Schafer M, Eiden L . Three types of tyrosine hydroxylase-positive CNS neurons distinguished by dopa decarboxylase and VMAT2 co-expression. Cell Mol Neurobiol. 2006; 26(4-6):659-78. PMC: 4183211. DOI: 10.1007/s10571-006-9053-9. View

15.

Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman G . Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther. 1998; 5(7):938-45. DOI: 10.1038/sj.gt.3300680. View

16.

Cunningham J, Oiwa Y, Nagy D, Podsakoff G, Colosi P, Bankiewicz K . Distribution of AAV-TK following intracranial convection-enhanced delivery into rats. Cell Transplant. 2001; 9(5):585-94. DOI: 10.1177/096368970000900504. View

17.

Szerlip N, Walbridge S, Yang L, Morrison P, Degen J, Jarrell S . Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles. J Neurosurg. 2007; 107(3):560-7. DOI: 10.3171/JNS-07/09/0560. View

18.

Ding D, Kanaly C, Bigner D, Cummings T, Herndon 2nd J, Pastan I . Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J Neurooncol. 2009; 98(1):1-7. PMC: 3082317. DOI: 10.1007/s11060-009-0046-7. View

19.

Nutt J, Burchiel K, Comella C, Jankovic J, Lang A, Laws Jr E . Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003; 60(1):69-73. DOI: 10.1212/wnl.60.1.69. View

20.

Su X, Kells A, Huang E, Lee H, Hadaczek P, Beyer J . Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther. 2009; 20(12):1627-40. PMC: 2861959. DOI: 10.1089/hum.2009.103. View